CONCLUSION:
The addition of clinical pharmacist services to cardiac rehabilitation program had resulted in marked decrease in hs-CRP, LVESV and LVEDV. Future studies are required to confirm our results. Finally, future studies are needed to evaluate the impact of clinical pharmacist-provided services addition to cardiac rehabilitation program on CVD morbidity and mortality among post-ACS patients.